Compare ALTI & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | PRLD |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | 490 | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.8M | 529.1M |
| IPO Year | 2021 | 2020 |
| Metric | ALTI | PRLD |
|---|---|---|
| Price | $3.16 | $4.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 155.0K | ★ 517.2K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.11 | 23.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $254,956,000.00 | $12,140,000.00 |
| Revenue This Year | $18.06 | $320.10 |
| Revenue Next Year | $10.71 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 23.21 | ★ 73.43 |
| 52 Week Low | $2.75 | $0.98 |
| 52 Week High | $5.45 | $6.83 |
| Indicator | ALTI | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 36.49 | 36.21 |
| Support Level | $2.87 | $3.92 |
| Resistance Level | $3.97 | $4.69 |
| Average True Range (ATR) | 0.21 | 0.39 |
| MACD | -0.08 | -0.19 |
| Stochastic Oscillator | 21.07 | 5.19 |
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.